Form 4 for ABOS Acumen Pharmaceuticals, Inc.
Accepted 2024-01-19 00:00:00 ET · period of report 2024-01-18 · accession 0001576885-24-000026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-19 | 2024-01-18 | ABOS | Zuga Matt | CFO, Chief Business Off | S - Sale | $3.71 | -4,242 | 211.4K | -2% | -$15.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-18 | S | D | 4,242 | $3.71 | 211,445 | D | — | — | (F1) Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2023. |